215 related articles for article (PubMed ID: 18044134)
1. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).
Ferrara AM
Clin Interv Aging; 2007; 2(2):179-87. PubMed ID: 18044134
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
Hoeffken G; Talan D; Larsen LS; Peloquin S; Choudhri SH; Haverstock D; Jackson P; Church D
Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):772-5. PubMed ID: 15605184
[TBL] [Abstract][Full Text] [Related]
3. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
Xu S; Xiong S; Xu Y; Liu J; Liu H; Zhao J; Xiong W
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):421-4. PubMed ID: 17120738
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
Balfour JA; Lamb HM
Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
[TBL] [Abstract][Full Text] [Related]
9. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
Yuan X; Liang BB; Wang R; Liu YN; Sun CG; Cai Y; Yu XH; Bai N; Zhao TM; Cui JC; Chen LA
J Chemother; 2012 Oct; 24(5):257-67. PubMed ID: 23182045
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Wispelwey B; Schafer KR
Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin: a respiratory fluoroquinolone.
Miravitlles M; Anzueto A
Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
[TBL] [Abstract][Full Text] [Related]
14. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
Ludlam HA; Enoch DA
Int J Antimicrob Agents; 2008 Aug; 32(2):101-5. PubMed ID: 18571380
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin in respiratory tract infections.
Miravitlles M
Expert Opin Pharmacother; 2005 Feb; 6(2):283-93. PubMed ID: 15757424
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin in the treatment of hospitalised community acquired pneumonia in HIV-infected subjects.
Bassetti M; Rosso R; Tosi C; DI Biagio A; Righi E; Viscoli C
J Chemother; 2007 Feb; 19(1):104-5. PubMed ID: 17309861
[No Abstract] [Full Text] [Related]
19. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
Ball P
Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
